Maudsley Deprescribing Guide
Safely Stop Psychiatric Meds
Free · In‑App Purchases · Designed for iPad
Provides evidence-based recommendations for safely reducing or stopping psychiatric medications with aim to improve patient outcomes & minimize withdrawal
"Try before you buy"-Download the FREE App,which includes sample content. In-App purchase required to unlock all content.
The Maudsley Deprescribing Guidelines provide evidence-based recommendations for safely discontinuing antidepressants, benzodiazepines, gabapentinoids, and Z-drugs. This resource is essential for healthcare professionals aiming to optimize patient care and minimize medication-related harm. It emphasizes a patient-centered approach, ensuring that deprescribing is conducted thoughtfully and effectively.
Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so.
The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment.
This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts).
Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as:
- Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs
- Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process
- Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat
- The difference between physical dependence and addiction/substance use disorder
- Explanation of why and how to implement hyperbolic tapering in clinical practice
- Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches
- Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual
- Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse.
- Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.
Disclaimer : App developers do not endorse or recommend any specific medications. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
Content licensed from printed ISBN 10: 1119823021
Content licensed from printed ISBN 13: 9781119823025
If you have any questions or comments,email us any time:customersupport@skyscape.com or call 508-299-3000
Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms & Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx
Author:Deanna Mark Horowitz; David M. Taylor
Publisher:Wiley-Blackwell
Ratings & Reviews
This app hasn’t received enough ratings or reviews to display an overview.
The developer, Skyscape Medpresso Inc, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .
Data Used to Track You
The following data may be used to track you across apps and websites owned by other companies:
- Identifiers
Data Not Linked to You
The following data may be collected but it is not linked to your identity:
- User Content
- Browsing History
- Identifiers
- Usage Data
- Diagnostics
Accessibility
The developer has not yet indicated which accessibility features this app supports. Learn More
Information
- Seller
- Skyscape Medpresso Inc
- Size
- 156.5 MB
- Category
- Medical
- Compatibility
Requires iOS 13.0 or later.
- iPhone
Requires iOS 13.0 or later. - iPad
Requires iPadOS 13.0 or later. - iPod touch
Requires iOS 13.0 or later. - Mac
Requires macOS 11.0 or later and a Mac with Apple M1 chip or later. - Apple Vision
Requires visionOS 1.0 or later.
- Languages
- English
- Age Rating
16+
- 16+
- Frequent
Medical Treatment information
- In-App Purchases
Yes
- Maudsley Deprescribing Guide $48.99
- Copyright
- © (c) 1998-2030 Skyscape Medpresso, Inc. All rights reserved.